Clifford Chance has advised Eurazeo Investment Manager on the financing granted to the international private equity fund Keensight Capital for the acquisition of Inke, a Spanish company leader in micronization of complex Active Pharmaceutical Ingredients (API) belonging to the Neuraxpharm pharmaceutical group.
The firm financing team was led by Global Financial Markets Partner Rodrigo Uría and associate María Vispo. The transaction is the 8th sponsor-led financing arranged in the Iberian Peninsula.
Set up in 1980 and based in Castellbisbal near Barcelona (Spain), Inke is the leader in micronization of complex Active Pharmaceutical Ingredients (“APIs”). The group has a specialization in inhalation APIs with a differentiated first-to-market approach. Inke combines a high regulatory expertise with close-knit relationships with major pharmaceutical companies worldwide, including in core markets such as the US, the EU and the highly regulated Japanese market.
Eurazeo is a leading global investment company, with a diversified portfolio of €35 billion in
assets under management, including nearly €24.7 billion from third parties, invested in
around 600 companies.